BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value
The company will begin discussions with regulators in the US and Europe for a gene therapy for hemophilia A based on the results of new data, with a launch targeted for late 2020. Durability remains a question.
You may also be interested in...
Just one of four accelerated assessment requests that were decided on at the European Medicines Agency this month is known to have been granted – for BioMarin’s Valrox. There was rejection for Amarin; Roche and Orchard are keeping the outcomes to themselves.
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.